Your fact-checks will appear here
Development of drugs for Alzheimer's disease, including targets such as amyloid, tau, and neurotransmitter receptors
There is no reliable, conclusive evidence that Neurocept capsules “repair” dementia-damaged brain cells; marketing materials portray broad cognitive benefits while independent reviews and regulators w...
Low‑dose methylene blue (and its reduced proprietary forms LMTM/HMTM) remains under active clinical investigation for Alzheimer’s disease (AD) in a small set of randomized trials that focus on short‑t...
The clinical literature contains a small number of trials that have administered Bacopa monnieri to people with Alzheimer’s disease, but none constitute incontrovertible, high‑quality evidence: a 2022...
There is no guaranteed way to prevent Alzheimer’s disease or all forms of dementia, and major public health sites state outright that no approach has been proven to prevent dementia conclusively . Sti...
Clinical and observational research consistently supports physical exercise—particularly and resistance (strength) training—as interventions that help preserve cognition, reduce biological markers lin...
has attracted repeated calls for to test whether it can prevent or treat or , but the published and registered work to date consists mainly of small, heterogeneous randomized trials and a single phase...
Reporting assembled for this brief finds no detailed, peer‑reviewed randomized controlled trial (RCT) record for a drug explicitly named “Neurocept” in the provided sources; the only source that menti...
There are no data in the provided reporting that describe the composition, pharmacology, or clinical testing of a product called “Neuro Defender,” so a definitive, evidence-based statement about direc...